$RVMD earnings report

Revolution Medicines entered a commercial stage during the third quarter with the August 26, 2026 U.S. approval and immediate launch of RASONQUE. RASONQUE generated $197.6 million of net product revenue during approximately five weeks of commercial availability. The launch reached more than 5,000 unique U.S. patients from approval through September 30, 2026, and claims have been reimbursed across health plans representing greater than 90% of U.S. PDAC covered lives. The company also cited its inclusion in NCCN Guidelines as a Category 1 Preferred subsequent-therapy option for appropriate pancreatic cancer patients.

The initial revenue figure has unusual launch-period composition. Management said it included patients transitioning from the Expanded Access Program, patients who had exhausted available options while awaiting approval, newly eligible patients and initial channel inventory stocking. It specifically identified the Expanded Access transition and initial waiting cohort as finite early-launch dynamics and said third-quarter results should not be viewed as indicative of the launch's longer-term trajectory. Cost of sales was $0.3 million, but the company said it was not representative of normalized cost of sales because manufacturing costs for product sold had previously been expensed to research and development.

Investment remained elevated across both development and commercialization. Research and development expense was $417.1 million, compared with $262.5 million in the prior-year quarter, driven by clinical trial and manufacturing expenses for RASONQUE, zoldonrasib and RMC-5127, additional headcount and stock-based compensation. Selling, general and administrative expense was $153.3 million, compared with $52.8 million, reflecting headcount, commercial-launch costs and stock-based compensation. The resulting net loss was $407.5 million, compared with a net loss of $305.2 million, and included a $40.7 million non-cash warrant fair-value charge.

Liquidity stood at $3.7 billion of cash, cash equivalents and marketable securities as of September 30, 2026, excluding $250 million received in October from the mandatory first Royalty Pharma debt tranche. The company did not draw the optional $250 million third royalty tranche and said up to an additional $1 billion remains available, subject to specified milestones. Management reiterated full-year 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion, including expected non-cash stock-based compensation expense of $270 million to $290 million. The next operational milestones include the pending European Commission decision, completion of RASolute 303 enrollment in the first half of 2027 and an anticipated initial RASolve 301 readout in 2027.

Revolution Medicines' second-quarter report centered on regulatory execution for daraxonrasib and further expansion of its RAS-targeted clinical portfolio. The FDA accepted the daraxonrasib NDA for previously treated metastatic PDAC, while the company also began an FDA-cleared Expanded Access Program in May. The company stated that daraxonrasib had been distributed on behalf of more than 2,000 patients through participating sites across nearly all 50 U.S. states and Puerto Rico. It also reported U.S. commercial launch readiness, if approved, and began EMA submissions under a phased review process.

The income statement reflects the cost of advancing late-stage trials, manufacturing, personnel, and commercialization preparation. Research and development expenses were $ 394,919 for the three months ended June 30, compared with $ 224,134 in the prior-year quarter. General and administrative expenses were $ 110,213, compared with $ 40,580. Total operating expenses were $ 505,132, and net loss was $ (644,371), compared with $ (247,787). The quarter's net loss included a non-cash charge of $151.0 million from the change in fair value of warrants assumed in the EQRx acquisition.

The company materially increased its financial resources during the quarter. Cash, cash equivalents and marketable securities were $ 3,937,969 as of June 30, 2026, compared with $ 2,025,679 as of December 31, 2025. The balance reflected April offerings that generated $2,225.0 million of gross proceeds and a $250.0 million Royalty Pharma payment received in May. The company also cited up to an additional $1.5 billion in committed, flexible capital under the Royalty Pharma arrangements, subject to milestone achievement. No capital returns were reported.

Clinical momentum extended into NSCLC. Zoldonrasib plus standard of care reported an ORR of 82% and DCR of 100% in the disclosed first-line RAS G12D NSCLC analysis, while elironrasib plus standard of care reported a confirmed ORR of 85%, DCR of 97%, and 95% of patients progression-free at 6 months in first-line RAS G12C NSCLC. These data support the company's Phase 3 plans, including planned initiation of RASolve 307 in the fourth quarter of 2026. The FDA also granted Breakthrough Therapy Designation to daraxonrasib in certain previously treated metastatic RAS mutant NSCLC.

For full-year 2026, Revolution Medicines updated GAAP operating expense guidance to $2.1 to $2.2 billion, including estimated non-cash stock-based compensation expense of between $270 and $290 million. The principal operational focus is now execution across the daraxonrasib regulatory review and potential launch, completion and initiation of planned Phase 3 studies, and continued investment in the broader RAS(ON) portfolio. The filing did not provide revenue guidance, profitability guidance, operating cash flow, free cash flow, or a prior outlook for comparison.